The COVID epidemic in Italy: Technogenetics at the forefront
02/20/2020
The national media spread the news of the first Italian case of COVID-19, acute pneumonia caused by the new coronavirus strain. The "patient 1" is hospitalized in critical condition at the ASST of Codogno and then transferred between 21 and 22 February in the San Matteo of Pavia.
02/24/2020
Since the first contagions recorded in Italy Technogenetics, which is based in the Lodi area, has adopted stringent measures that have anticipated the subsequent directives and have always been perfectly in line with the recommendations of the Health and Political Authorities, thus promoting high safety standards for all the staff and ensuring full support for the entire health sector. The research, production and quality control activities have been reprogrammed over two shifts in order to limit access to the production departments and intensify production. Incoming employees are still being measured body temperature and at the same time we have inhibited visits to uncontrolled external visitors. All the collaborators of the commercial and administrative offices, however, continued their Smart Working activities. To date, none of the 110 Technogenetics collaborators have symptoms or tested positive for the COVID-19 virus
03/16/2020
The RT-PCR molecular kits, the POCT rapid test and the ELISA serological kits (IgG, IgM) obtain CE certification.
03/20/2020
Technogenetics launches the Rapid Test COVID-19 IgM / IgG antibody detection for the qualitative detection of IgG and IgM antibodies against SARS-CoV-2 in serum, plasma and human whole blood samples. The kit allows fast screening in critical environments and is one of the most accredited rapid tests in China and Korea that has contributed to the containment of the infection thanks to the ability to detect even asymptomatic patients at very low costs.
03/23/2020
Validations of the molecular test in real time-PCR advanced, a cutting-edge test for the qualitative detection of SARS-CoV-2 nucleic acid targeting the ORF1ab region, and the genes of the N and E proteins of the viral genome have been launched.
Today
In our laboratories serological chemiluminescence tests (CLIA) are being developed for a quantitative detection of the antibody response in COVID-19 patients. The kits to complete the entire line will be ready by the first half of April.